Posaconazole Dr. Reddy's Indications/Uses

POSACONAZOLE DR. REDDY'S Modified Release Tablets is indicated for use in the treatment of the following fungal infections in adults: Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; Fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients with disease that is refractory to other therapy or patients who are intolerant of other therapy.
Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
POSACONAZOLE DR. REDDY'S Modified Release Tablets is also indicated for prophylaxis of invasive fungal infections in the following adult patients: Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high-risk of developing invasive fungal infections.
Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.
POSACONAZOLE DR. REDDY'S Modified Release Tablets are not indicated for the treatment of oropharyngeal candidiasis. Refer to the package insert of Posaconazole oral suspension for use in oropharyngeal candidiasis.